title: Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo.
abstract: The pituitary tumor transforming (PTTG) gene family comprises PTTG1, 2, and 3. Forced expression of PTTG1 (securin) induces cellular transformation and promotes tumor development in animal models. PTTG1 is overexpressed in various human cancers. However, the expression and pathogenic implications of the PTTG gene family in hepatocellular carcinoma are largely unknown. Gene silencing using short interfering RNA (siRNA) has become an efficient means to study the functions of genes and has been increasingly used for cancer gene therapy approaches. We report that PTTG1, but not PTTG2 and 3, was highly and frequently expressed in liver cancer tissues from patients and highly in SH-J1, SK-Hep1, and Huh-7 hepatoma cell lines. Adenoviral vector encoding siRNA against PTTG1 (Ad.PTTG1-siRNA) depleted PTTG1 specifically and efficiently in SH-J1 hepatoma cells, which resulted in activation of p53 that led to increased p21 expression and induction of apoptosis. The depletion of PTTG1 in HCT116 colorectal cancer cells exhibited a cytotoxic effect in a p53-dependent manner. Ad.PTTG1-siRNA-mediated cytotoxic effect was dependent on expression levels of PTTG1 and p53 in hepatoma cell lines. Huh-7 hepatoma cells, once transduced with Ad.PTTG1-siRNA, displayed markedly attenuated growth potential in nude mice. Intra-tumor delivery of Ad.PTTG1-siRNA led to significant inhibition of tumor growth in SH-J1 tumor xenograft established in nude mice. In conclusion, PTTG1 overexpressed in hepatoma cell lines negatively regulates the ability of p53 to induce apoptosis. PTIG1 gene silencing using siRNA may be an effective modality to treat liver cancer, in which PTTG1 is abundantly expressed. Supplementary material for this article can be found on the HEPATOLOGY website (http://interscience.wiley.com/jpages/0270-9139/ suppmat/index.html).
authors.affiliation: Gene Therapy Research Unit, Korea Research Institute of Bioscience and Biotechnology, Yusong Daejeon, Republic of Korea.
authors.forename: Jung
authors.initials: J
authors.lastname: Cho-Rok
authors.forename: Jinsang
authors.initials: J
authors.lastname: Yoo
authors.forename: Ye Jin
authors.initials: YJ
authors.lastname: Jang
authors.forename: Sangsoo
authors.initials: S
authors.lastname: Kim
authors.forename: In-Sun
authors.initials: IS
authors.lastname: Chu
authors.forename: Young Il
authors.initials: YI
authors.lastname: Yeom
authors.forename: Jong Young
authors.initials: JY
authors.lastname: Choi
authors.forename: Dong-Soo
authors.initials: DS
authors.lastname: Im
mesh_terms: D000256:Adenoviridae; D000818:Animals; D017209:Apoptosis; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000473:pathology*; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009363:Neoplasm Proteins / Q000235:genetics*; D034741:RNA, Small Interfering / Q000235:genetics*; D064249:Securin; D015534:Trans-Activators / Q000235:genetics*; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000502:physiology
chemical_list: D009363:Neoplasm Proteins; D034741:RNA, Small Interfering; D064249:Securin; D015534:Trans-Activators; D016159:Tumor Suppressor Protein p53; C578002:pituitary tumor-transforming protein 1, human; C578003:pituitary tumor-transforming protein 2, human